Tesamorelin vs CJC-1295: GHRH Analog Research Comparison
Compare tesamorelin (FDA-approved GHRH analog) and CJC-1295 — pharmacokinetics, pulsatility, IGF-1 response, and published research findings.
Tesamorelin and CJC-1295 are both stabilised GHRH analogs, but they were developed for different research goals: tesamorelin for clinically validated visceral-adipose reduction; CJC-1295 for pulsatile or sustained GH-axis research depending on DAC variant. This comparison summarises the published literature relevant to laboratory research.
At-a-glance comparison
| Attribute | Tesamorelin | CJC-1295 | |---|---|---| | Class | GHRH analog (trans-3-hexenoyl-GRF(1-44)) | GHRH analog (tetra-substituted GRF(1-29)) | | Stabilisation strategy | N-terminal acyl group resists DPP-IV | Tetra-substitution + optional DAC albumin tether | | Half-life | ~26-38 minutes (subcutaneous) | ~30 min (no-DAC) or ~8 days (DAC) | | Pulsatility | Preserved | Preserved (no-DAC); tonic (DAC) | | Regulatory status | FDA-approved (Egrifta) for HIV lipodystrophy | Research only | | Most-cited research endpoint | Visceral adipose tissue reduction | IGF-1 elevation, GH pulse amplitude |
Mechanism
Both bind the pituitary GHRH receptor on somatotrophs and trigger endogenous pulsatile GH release. Both preserve negative-feedback regulation by somatostatin and IGF-1 — distinguishing them from exogenous GH administration. The structural difference is the stabilisation strategy: tesamorelin uses an N-terminal acyl modification; CJC-1295 uses backbone substitution plus optional DAC albumin binding.
Pharmacokinetics — the central distinction
Tesamorelin's half-life sits between sermorelin (~10-20 min) and CJC-1295 no-DAC (~30 min) — close enough to native GHRH to preserve pulsatility. CJC-1295 DAC's ~8-day half-life produces tonic GHRH-receptor exposure, a fundamentally different signalling pattern that elevates basal IGF-1 across the dosing interval.
Published research highlights
- Tesamorelin's Phase 3 trials in HIV-associated lipodystrophy demonstrated significant visceral adipose tissue reduction (~15-18%) at 26 weeks, leading to FDA approval as Egrifta.
- CJC-1295 (no-DAC) is most-cited in combination research with ghrelin-receptor agonists (ipamorelin, GHRP-2) for additive GH pulse amplitude.
- CJC-1295 DAC research is most-cited for sustained IGF-1 elevation from weekly dosing.
Selecting between them in research
- For published clinical-translation context: tesamorelin (FDA precedent for VAT reduction).
- For pulsatile GH-axis research: tesamorelin or CJC-1295 no-DAC.
- For sustained tonic IGF-1 elevation with weekly dosing: CJC-1295 DAC.
Frequently asked research questions
Why has tesamorelin advanced clinically while CJC-1295 hasn't? Tesamorelin had a specific clinical indication (HIV-lipodystrophy VAT) with measurable endpoints. CJC-1295's broader research positioning never crystallised into a single Phase 3 indication.
Do they share the same safety signature? Both classes share the GHRH-class profile: injection-site reactions, transient glucose elevation, fluid retention at higher doses. Tesamorelin has the larger controlled-trial safety dataset.
Related research
- HGH vs Tesamorelin research comparison
- CJC-1295 vs Ipamorelin research comparison
- CJC-1295 vs Sermorelin research comparison
Related Research Articles
PT-141 vs Kisspeptin-10 — Research Comparison (2026)
PT-141 vs kisspeptin-10 for sexual-response research: central melanocortin pathway vs upstream HPG-axis activation.
Ipamorelin vs MK-677 — Research Comparison (2026)
Ipamorelin (peptide GHRP) vs MK-677/ibutamoren (oral ghrelin mimetic): selectivity, route, half-life and IGF-1 effects.
Epitalon vs SS-31 — Research Comparison (2026)
Epitalon vs SS-31 (elamipretide): pineal/telomerase research peptide vs mitochondria-targeted cardiolipin peptide.
Gonadorelin vs Kisspeptin-10 — Research Comparison (2026)
Gonadorelin vs kisspeptin-10: direct GnRH-receptor agonism vs upstream KISS1R signaling for HPG-axis research.
Tirzepatide vs Cagrilintide — Research Comparison (2026)
Tirzepatide vs cagrilintide compared: dual GIP/GLP-1 incretin vs long-acting amylin analog, mechanism, dosing and stacking research.
AOD-9604 vs Semaglutide — Research Comparison (2026)
AOD-9604 vs semaglutide for body-composition research: lipolysis-targeted GH fragment vs GLP-1 receptor agonist.
Related Research Materials
Parent Research Hubs
Recombinant human growth hormone (somatropin) is one of the most extensively studied endocrine compounds in the published literature. This hub aggregates Ares Research's HGH reference material — receptor signalling, dose-response, body composition, longevity, and head-to-head comparisons with peptide GH-axis modulators.
Explore hub →Tesamorelin is a synthetic 44-amino-acid analog of growth hormone releasing hormone (GHRH) with a stabilising trans-3-hexenoyl modification at the N-terminus. It is one of the most thoroughly characterised GHRH analogues in the clinical literature, particularly for studies of visceral adipose tissue and the GH/IGF-1 axis.
Explore hub →CJC-1295 is a tetrasubstituted GHRH(1-29) analog studied in two forms: with a drug-affinity complex (DAC) that binds serum albumin and extends half-life to days, and without DAC (also called Mod GRF 1-29) for short, pulsatile GH stimulation.
Explore hub →Neutral, moderated research discussion. Laboratory use only.
More compound guides, hubs, and educational research materials.